Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of XKH001 in adults with moderate-to-severe atopic dermatitis
CTR20244037Phase 2Active
- Sponsor
- Zhejiang Xinkanghe Biopharmaceutical Technology
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of xkh001 in atopic dermatitis (AD), sponsored by Zhejiang Xinkanghe Biopharmaceutical Technology. Started Dec 2024; status: active.
02
Drugs
xkh001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20244037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244037.